DRRX DURECT CORP Product Launches 8-K Filing 2024 - Trial Announcement DURECT Corporation announced the design of its Phase 3 trial for larsucosterol, a treatment for severe alcohol-associated hepatitis, and corrected a previous filing error regarding the press release link.Get access to all SEC 8-K filings of the DURECT CORP